## Benchmarking and Exchange Beyond Company's Boarders in MedTech


Transforming selfcare, Transforming Ypsomed

Lausanne, 03. September 2024






### Solutions for healthcare's biggest challenge are our growth drivers









#### Selfcare

Improving quality of life, therapy adherence and supporting affordable healthcare systems

#### Biologics

Most new-generation drugs with complex active pharmaceutical ingredients have to be injected

#### Biosimilars


Expanding global access to affordable medical care

#### Digitization

Enabling innovative, digital therapy management for optimal therapy outcomes and evidence-based care



### Chronic diseases - the biggest challenge for the healthcare system



Six in ten adults in the US have a chronic disease



Average adherence rate of people with chronic conditions




### **Ypsomed's Platform Approach – Generate standards that enable multiplication**






### Self-treatment becomes a matter of course Better therapy results for chronic diseases





### Our accelerated investment program Ypsomed 2030 Capacity for around 1 billion devices p.a. in 2030




- Investing over CHF 1.5 billion in production infrastructure over the coming five years:
  - Expansion at the Solothurn site
  - Expansion (hall D) in Schwerin
  - Construction of new plant in China
  - Construction of new plant «Schwerin II»
  - Construction of new plant in North America
- Recruitment of >1,000 employees on the store floor by 2029



### Ypsomed is both innovation- and cost-leader

Fully automated production lines up to 220 ppm / 95% in-house production incl toolmaking, plastic and spring production







#### **Growth of > 25% for continuing business per year**




- 10 million patients worldwide with chronic diseases rely on YPSOMED products every day
- YPSOMED is the fastest growing Medtech company in Europe
- Investors expect Ypsomed to implement its growth plans without compromise



### Capacity expansion not only with new infrastructure Resilience and risk mitigation with efficiency improvements


- The focus is not only on new systems, but also on increasing the efficiency of existing infrastructure
- Lean-Maintenance Program is active since 2022
- Conventional ways of improving Assembly-line stability are no longer sufficient
- Next step "benchmarking beyond"






### 1. Transformation to a scalable value stream organization Focus on ValueStreams - moving away from the functional organization

 ValueStream organization is key for benchmarking activities






 ValueStream has all production equipment and personnel to produce from raw-material a Medical-Device on 40x50m (2'000m²)




# 2. Process mapping -> complete transparency across the value chain Process-Mining ensures that we do not scale inadequate processes, knowledge and procedures


- Process model maps the production value stream
- Production orders for 400 million pens and 8.5 bn IM-parts are analyzed
- Each process step can be used as a benchmark comparison within the process industry





### Interesting observations made with process mining








### Data-Mining for highly dynamic thermal production processes 500 relevant data points per second / parallel on 400 production lines

- Experience can also blind the experts
- Optical in-process quality control also relevant for food producers in bottling plants
- Other process industries also have thermal problems with a wide variety of plastics





### 3. Process model and data mining enables benchmarking with process industry companies

- No competitive risks when comparing process data
- Different views and new opinions on old internal process problems
- Ypsomed regularly compares itself with production teams from 5 well-known companies in the process industry
  - Packaging industry
  - Food industry
  - Plumbing equipment
  - Diagnostics



